Original Research Article

DOI: https://dx.doi.org/10.18203/2394-6040.ijcmph20211744

Perception, practices and preparedness of the adult population in response to SARS CoV-2 pandemic in India

Arpita Jain, Manju Toppo, Devendra Gour, Shipra Verma*

Department of Community Medicine, Gandhi Medical College, Bhopal, Madhya Pradesh, India

Received: 07 December 2020 Revised: 14 March 2021 Accepted: 15 March 2021

*Correspondence: Dr. Shipra Verma,

E-mail: shipra3092@gmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Background: COVID-19 infection is a highly contagious disease and has affected a large population. As COVID-19 is a new disease and is having the most devastating effects globally, its emergence and spread, causes confusion, anxiety and fear among the general public. Objectives of the study were to know the preparedness measures adopted by the community by large in the beginning of epidemic of COVID-19 and to find out the perceptions and behavioral change of the community regarding COVID-19.

Method: A cross sectional survey was conducted amongst the residents of India from 11th April 20 to 30th May 20. It was an online study. An online semi-structured questionnaire having both open and close ended questions was developed by using Google forms, with a consent form appended to it. Data was collected in Google form and was reentered in MS excel and analyzed using EPIINFO.

Results: Out of 301 study participants majority i.e., 162 (53.8%) of them were male. Majority of the participants were in the age group of 21-30. Occupation status of the respondents revealed that doctor accounted for 125 (41.5%). Only, 24 (8%) had chronic illness. Awareness regarding COVID-19 was 297 (98.7%).

Conclusions: Perceptions have a great role in behavioral change.

Keywords: COVID-19, Novel corona virus, Pandemic, Hand wash, Mask, Social distancing

INTRODUCTION

The microbial world is mysterious, threatening and scary to many people. Addressing these participants is a necessary part of planning for infectious biological disasters. The only counter measures available early in an outbreak of a new infectious disease are behavior interventions such as quarantine, hygiene and isolation.¹ Clinical condition caused by novel corona virus is called as COVID-19.2,3 On 30th January 2020, the world health organization declared COVID-19 to be a public health emergency of international concern.4

COVID-19 is a highly contagious disease and has affected a large population, the total number of deaths caused due to COVID-19 has exceeded that caused by any of its predecessors.5As COVID-19 is a new disease

and is having the most devastating effects globally, its emergence and spread cause's confusion, anxiety and fear among the general public. Social stigma has arisen as certain population is being targeted as being the reason for the outbreak. It is vital to avoid stigma as it can make people hide their illness and do not seek health care immediately.5 Therefore, present study was an effort to assess the knowledge, attitude, practice and preparedness of COVID-19 by exploring coping strategies and health behaviors enacted in response to COVID-19 pandemic.

Objectives

Objectives of the study were to know the preparedness measures adopted by the community by large in the beginning of epidemic of COVID-19 and to find out the perceptions and behavioral change of the community regarding COVID-19.

METHODS

Study design

The study design use was cross sectional study.

Study area

All across the country and study participants were citizens of India

Study duration

The study deration was from 11^{th} of April 2020-to 30^{th} of May 2020 for one month.

Sampling technique

The sampling technique used is Snowball technique.

Inclusion criteria

The study included the participants with access to WhatsApp, participants with age more than 18 years, able to understand English and willing to give consent.

Study plan

An online semi-structured questionnaire having both open and close ended questions was developed by using Google forms, with a consent form appended to it. The link was sent through WhatsApp. The study started with the first participant and using Snowball sampling technique, the participants were encouraged to roll out the survey to as many known people as possible in their contacts in their respective phones. Thus, the link was forwarded to people apart from the first point of contact and so on. On receiving and clicking the link the participants got auto directed to the information about the study and informed consent. After they accepted to take the survey, they had to fill the first section which constituted details regarding socio-demographic details. Then a set of several questions appeared sequentially, which the participants were to answer which mainly consisted of awareness, knowledge, practices, preparedness for the pandemic, and preventive measures against COVID-19. We received a total of 327 acceptance but only 301 participants responded to the entire question. Hence analyses of only 301 participants were done. Study was approved by the institutional ethical committee. Data was collected in Google form and was reentered in MS excel and analyzed using EPINFO.

RESULTS

Out of 301 study participants majority i.e., 162 (53.8%) of them were male. Majority of the participants were in

the age group of 21-30 years with the mean and standard deviation of 30 ± 11.3 . Occupation status of the respondents revealed that Doctor accounted for 125 (41.5%), students 69 (22.9%), engineer 17 (5.6%) and business 12 (4%). Only, 24 (8%) had chronic illness.

Table 1: Socio demographic profile of the study participants (n=301).

Variables	Numbers	Percentage (%)			
Gender					
Male	162	53.8			
Female	139	46.2			
Age (year)					
≤20	27	9.0			
21-30	179	59.5			
31-40	46	15.3			
41-50	25	8.3			
51-60	14	4.7			
>60	10	3.3			
Occupation					
Doctor	125	41.5			
Student	69	22.9			
Engineer	17	5.6			
Business	12	4			
Nurse	09	3			
Government employee	07	2.3			
Housewife	07	2.3			
Teacher	12	4			
Lawyer	03	1			
Banker	02	0.7			
Computer operator	02	0.7			
Army	01	0.3			
Actor	01	0.3			
Others	37	12.3			
Do you have a	Do you have a chronic illness?				
Ye	24	8			
No	262	87			
Don't know	15	5			

Awareness regarding COVID-19, regarding the modes of transmission was very well amongst study participants. Regarding people who are at risk of getting COVID-19 infection, participants were well informed about who are more vulnerable and are at a greater risk of getting infection. From the responses elicited from the participants regarding symptoms of COVID-19, fever was the most prominent symptom followed by shortness of breath, cough, sore throat, tiredness, muscle stiffness, headache, anosmia and diarrhea respectively. The availability of drug for COVID-19 was affirmed by very few of the participants of which only i.e., 23 (88.5%) of participants said that HCQ was the drug of choice. Regarding incubation period of COVID-19 most of them knew about the duration 14 days.

Table 2: Awareness and knowledge of study participants regarding COVID-19 (n=301).

Awareness regarding COVID-19 Yes 297 98.7 No 04 1.3 Mode of transmission 293 97.4 Respiratory droplets 293 97.4 Touching contaminated surface/object 219 72.8 Contaminated food and water 70 23.2 At risk individual 260 years 299 99.3 Lung disease 293 97.3 Diabetes 283 94 Asthma 287 95.3 Heart disease 269 89.4 Pregnant women 260 86.4 Infant 257 85.4 Children 1-5 years 239 79.4 Symptoms Fever 288 95.7 Shortness of breath 286 95 Cough 275 91.4 Sore throat 243 80.7 Tiredness 178 59.1 Stiffness of muscle 163 54.2 Headache 16	Variables	Numbers	Percentage (%)	
No 04 1.3 Mode of transmission Respiratory droplets 293 97.4 Touching contaminated surface/object 219 72.8 Contaminated food and water 70 23.2 At risk individual ≥60 years 299 99.3 Lung disease 293 97.3 Diabetes 283 94 Asthma 287 95.3 Heart disease 269 89.4 Pregnant women 260 86.4 Infant 257 85.4 Children 1-5 years 239 79.4 Symptoms Fever 288 95.7 Fever sof breath 286 95 Cough 275 91.4 Sore throat 243 80.7 Tiredness 178 59.1 Stiffness of muscle 163 54.2 Headache 165 54.8 Runny nose 157 52.2 Anosmia 133 44.2 Diarrhea 110 36.5 Drug a	Awareness regarding CO	VID-19		
Mode of transmission Respiratory droplets 293 97.4 Touching contaminated surface/object 219 72.8 Contaminated food and water 70 23.2 At risk individual ≥60 years 299 99.3 Lung disease 293 97.3 Diabetes 283 94 Asthma 287 95.3 Heart disease 269 89.4 Pregnant women 260 86.4 Infant 257 85.4 Children 1-5 years 239 79.4 Symptoms Fever 288 95.7 Shortness of breath 286 95 Cough 275 91.4 Sore throat 243 80.7 Tiredness 178 59.1 Stiffness of muscle 163 54.2 Headache 165 54.8 Runny nose 157 52.2 Anosmia 133 44.2 Diarrhea 110 36.5 <td>Yes</td> <td>297</td> <td>98.7</td>	Yes	297	98.7	
Respiratory droplets 293 97.4 Touching contaminated surface/object 219 72.8 Contaminated food and water 70 23.2 At risk individual 260 years 299 99.3 Lung disease 293 97.3 Diabetes 283 94 Asthma 287 95.3 Heart disease 269 89.4 Pregnant women 260 86.4 Infant 257 85.4 Children 1-5 years 239 79.4 Symptoms Fever 288 95.7 Shortness of breath 286 95 Cough 275 91.4 Sore throat 243 80.7 Tiredness 178 59.1 Stiffness of muscle 163 54.2 Headache 165 54.8 Runny nose 157 52.2 Anosmia 133 44.2 Diarrhea 110 36.5 Drug available	No	04	1.3	
Touching contaminated surface/object 219 72.8 Contaminated food and water 70 23.2 At risk individual ≥60 years 299 99.3 Lung disease 293 97.3 Diabetes 283 94 Asthma 287 95.3 Heart disease 269 89.4 Pregnant women 260 86.4 Infant 257 85.4 Children 1-5 years 239 79.4 Symptoms Fever 288 95.7 Shortness of breath 286 95 Cough 275 91.4 Sore throat 243 80.7 Tiredness 178 59.1 Stiffness of muscle 163 54.2 Headache 165 54.8 Runny nose 157 52.2 Anosmia 133 44.2 Diarrhea 110 36.5 Drug available for COVID-19 Yes 26 8.6	Mode of transmission			
surface/object 219 72.8 Contaminated food and water 70 23.2 At risk individual ≥60 years 299 99.3 Lung disease 293 97.3 Diabetes 283 94 Asthma 287 95.3 Heart disease 269 89.4 Pregnant women 260 86.4 Infant 257 85.4 Children 1-5 years 239 79.4 Symptoms Fever 288 95.7 Shortness of breath 286 95 Cough 275 91.4 Sore throat 243 80.7 Tiredness 178 59.1 Stiffness of muscle 163 54.2 Headache 165 54.8 Runny nose 157 52.2 Anosmia 133 44.2 Diarrhea 110 36.5 Drug available for COVID-19 Yes 26 8.6 No 260 86.4 Both drug and vaccine 23<	Respiratory droplets	293	97.4	
water At risk individual ≥60 years 299 99.3 Lung disease 293 97.3 Diabetes 283 94 Asthma 287 95.3 Heart disease 269 89.4 Pregnant women 260 86.4 Infant 257 85.4 Children 1-5 years 239 79.4 Symptoms Fever 288 95.7 Shortness of breath 286 95 Cough 275 91.4 Sore throat 243 80.7 Tiredness 178 59.1 Stiffness of muscle 163 54.2 Headache 165 54.8 Runny nose 157 52.2 Anosmia 133 44.2 Diarrhea 110 36.5 Drug available for COVID-19 Yes 26 8.6 No 260 86.4 Both drug and vaccine 23 88.5 Which drug is available? (n=26) Hydr		219	72.8	
≥60 years 299 99.3 Lung disease 293 97.3 Diabetes 283 94 Asthma 287 95.3 Heart disease 269 89.4 Pregnant women 260 86.4 Infant 257 85.4 Children 1-5 years 239 79.4 Symptoms Fever 288 95.7 Shortness of breath 286 95 Cough 275 91.4 Sore throat 243 80.7 Tiredness 178 59.1 Stiffness of muscle 163 54.2 Headache 165 54.8 Runny nose 157 52.2 Anosmia 133 44.2 Diarrhea 110 36.5 Drug available for COVID-19 Yes 26 8.6 No 260 86.4 Both drug and vaccine 2 2 Which drug is available? (n=26) Hydroxychloroquine 23 88.5 Antibiotic 01 3.8		70	23.2	
Lung disease 293 97.3 Diabetes 283 94 Asthma 287 95.3 Heart disease 269 89.4 Pregnant women 260 86.4 Infant 257 85.4 Children 1-5 years 239 79.4 Symptoms 79.4 79.4 Symptoms 895.7 89.7 Shortness of breath 286 95 Cough 275 91.4 Sore throat 243 80.7 Tiredness 178 59.1 Stiffness of muscle 163 54.2 Headache 165 54.8 Runny nose 157 52.2 Anosmia 133 44.2 Diarrhea 110 36.5 Drug available for COVID-19 Yes 26 8.6 No 260 86.4 Both drug and vaccine 06 2 Which drug is available? (n=26) Hydroxychloroquine 23 88.5 Antibiotic 01 3.8	At risk individual			
Diabetes 283 94 Asthma 287 95.3 Heart disease 269 89.4 Pregnant women 260 86.4 Infant 257 85.4 Children 1-5 years 239 79.4 Symptoms Fever 288 95.7 Shortness of breath 286 95 Cough 275 91.4 Sore throat 243 80.7 Tiredness 178 59.1 Stiffness of muscle 163 54.2 Headache 165 54.8 Runny nose 157 52.2 Anosmia 133 44.2 Diarrhea 110 36.5 Drug available for COVID-19 Yes 26 8.6 No 260 86.4 Both drug and vaccine 06 2 Which drug is available? (n=26) Hydroxychloroquine 23 88.5 Antibiotic 01 3.8 Don't know 02 7.7 Incubation period (days)	≥60 years	299	99.3	
Asthma 287 95.3 Heart disease 269 89.4 Pregnant women 260 86.4 Infant 257 85.4 Children 1-5 years 239 79.4 Symptoms Fever 288 95.7 Shortness of breath 286 95 Cough 275 91.4 Sore throat 243 80.7 Tiredness 178 59.1 Stiffness of muscle 163 54.2 Headache 165 54.8 Runny nose 157 52.2 Anosmia 133 44.2 Diarrhea 110 36.5 Drug available for COVID-19 Yes 26 8.6 No 260 86.4 Both drug and vaccine 06 2 Which drug is available? (n=26) Hydroxychloroquine 23 88.5 Antibiotic 01 3.8 Don't know 02 7.7 Incubation period (days) Up to 3 04 1.3	Lung disease	293	97.3	
Heart disease 269 89.4 Pregnant women 260 86.4 Infant 257 85.4 Children 1-5 years 239 79.4 Symptoms 79.4 79.4 Fever 288 95.7 Shortness of breath 286 95 Cough 275 91.4 Sore throat 243 80.7 Tiredness 178 59.1 Stiffness of muscle 163 54.2 Headache 165 54.8 Runny nose 157 52.2 Anosmia 133 44.2 Diarrhea 110 36.5 Drug available for COVID-19 Yes 26 8.6 No 260 86.4 Both drug and vaccine 2 2 Which drug is available? (n=26) Hydroxychloroquine 23 88.5 Antibiotic 01 3.8 Don't know 02 7.7 Incubation period (days)		283	94	
Pregnant women 260 86.4 Infant 257 85.4 Children 1-5 years 239 79.4 Symptoms 79.4 79.4 Fever 288 95.7 Shortness of breath 286 95 Cough 275 91.4 Sore throat 243 80.7 Tiredness 178 59.1 Stiffness of muscle 163 54.2 Headache 165 54.8 Runny nose 157 52.2 Anosmia 133 44.2 Diarrhea 110 36.5 Drug available for COVID-19 Yes 26 8.6 No 260 86.4 Both drug and vaccine 06 2 Which drug is available? (n=26) Hydroxychloroquine 23 88.5 Antibiotic 01 3.8 Don't know 02 7.7 Incubation period (days) Up to 3 04 1.3 Up	Asthma	287	95.3	
Infant 257 85.4 Children 1-5 years 239 79.4 Symptoms Fever 288 95.7 Shortness of breath 286 95 Cough 275 91.4 Sore throat 243 80.7 Tiredness 178 59.1 Stiffness of muscle 163 54.2 Headache 165 54.8 Runny nose 157 52.2 Anosmia 133 44.2 Diarrhea 110 36.5 Drug available for COVID-19 Yes 26 8.6 No 260 86.4 86.4 Both drug and vaccine 06 2 Which drug is available? (n=26) Hydroxychloroquine 23 88.5 Antibiotic 01 3.8 Don't know 02 7.7 Incubation period (days) Up to 3 04 1.3 Up to 7 19 6.3 Up to 14	Heart disease	269	89.4	
Infant 257 85.4 Children 1-5 years 239 79.4 Symptoms Fever 288 95.7 Shortness of breath 286 95 Cough 275 91.4 Sore throat 243 80.7 Tiredness 178 59.1 Stiffness of muscle 163 54.2 Headache 165 54.8 Runny nose 157 52.2 Anosmia 133 44.2 Diarrhea 110 36.5 Drug available for COVID-19 Yes 26 8.6 No 260 86.4 86.4 Both drug and vaccine 06 2 Which drug is available? (n=26) Hydroxychloroquine 23 88.5 Antibiotic 01 3.8 Don't know 02 7.7 Incubation period (days) Up to 3 04 1.3 Up to 7 19 6.3 Up to 14	Pregnant women	260	86.4	
Symptoms Fever 288 95.7		257	85.4	
Symptoms Fever 288 95.7	Children 1-5 years	239	79.4	
Fever 288 95.7 Shortness of breath 286 95 Cough 275 91.4 Sore throat 243 80.7 Tiredness 178 59.1 Stiffness of muscle 163 54.2 Headache 165 54.8 Runny nose 157 52.2 Anosmia 133 44.2 Diarrhea 110 36.5 Drug available for COVID-19 Yes 26 8.6 No 260 86.4 Both drug and vaccine 06 2 Which drug is available? (n=26) Hydroxychloroquine 23 88.5 Antibiotic 01 3.8 Don't know 02 7.7 Incubation period (days) Up to 3 04 1.3 Up to 7 19 6.3 Up to 14 272 90.2	-			
Cough 275 91.4 Sore throat 243 80.7 Tiredness 178 59.1 Stiffness of muscle 163 54.2 Headache 165 54.8 Runny nose 157 52.2 Anosmia 133 44.2 Diarrhea 110 36.5 Drug available for COVID-19 Yes 26 8.6 No 260 86.4 Both drug and vaccine 06 2 Which drug is available? (n=26) Hydroxychloroquine 23 88.5 Antibiotic 01 3.8 Don't know 02 7.7 Incubation period (days) Up to 3 04 1.3 Up to 7 19 6.3 Up to 14 272 90.2		288	95.7	
Sore throat 243 80.7 Tiredness 178 59.1 Stiffness of muscle 163 54.2 Headache 165 54.8 Runny nose 157 52.2 Anosmia 133 44.2 Diarrhea 110 36.5 Drug available for COVID-19 Yes 26 8.6 No 260 86.4 Both drug and vaccine 06 2 Which drug is available? (n=26) Hydroxychloroquine 23 88.5 Antibiotic 01 3.8 Don't know 02 7.7 Incubation period (days) Up to 3 04 1.3 Up to 7 19 6.3 Up to 14 272 90.2	Shortness of breath	286	95	
Sore throat 243 80.7 Tiredness 178 59.1 Stiffness of muscle 163 54.2 Headache 165 54.8 Runny nose 157 52.2 Anosmia 133 44.2 Diarrhea 110 36.5 Drug available for COVID-19 Yes 26 8.6 No 260 86.4 Both drug and vaccine 06 2 Which drug is available? (n=26) Hydroxychloroquine 23 88.5 Antibiotic 01 3.8 Don't know 02 7.7 Incubation period (days) Up to 3 04 1.3 Up to 7 19 6.3 Up to 14 272 90.2	Cough	275	91.4	
Stiffness of muscle 163 54.2 Headache 165 54.8 Runny nose 157 52.2 Anosmia 133 44.2 Diarrhea 110 36.5 Drug available for COVID-19 Yes 26 8.6 No 260 86.4 Both drug and vaccine 06 2 Which drug is available? (n=26) Hydroxychloroquine 23 88.5 Antibiotic 01 3.8 Don't know 02 7.7 Incubation period (days) Up to 3 04 1.3 Up to 7 19 6.3 Up to 14 272 90.2	Sore throat	243	80.7	
Headache 165 54.8 Runny nose 157 52.2 Anosmia 133 44.2 Diarrhea 110 36.5 Drug available for COVID-19 Yes 26 8.6 No 260 86.4 Both drug and vaccine 06 2 Which drug is available? (n=26) Hydroxychloroquine 23 88.5 Antibiotic 01 3.8 Don't know 02 7.7 Incubation period (days) Up to 3 04 1.3 Up to 7 19 6.3 Up to 14 272 90.2	Tiredness	178	59.1	
Runny nose 157 52.2 Anosmia 133 44.2 Diarrhea 110 36.5 Drug available for COVID-19 Yes 26 8.6 No 260 86.4 Both drug and vaccine 06 2 Which drug is available? (n=26) Hydroxychloroquine 23 88.5 Antibiotic 01 3.8 Don't know 02 7.7 Incubation period (days) Up to 3 04 1.3 Up to 7 19 6.3 Up to 14 272 90.2	Stiffness of muscle	163	54.2	
Anosmia 133 44.2 Diarrhea 110 36.5 Drug available for COVID-19 Yes 26 8.6 No 260 86.4 Both drug and 06 2 Which drug is available? (n=26) Hydroxychloroquine 23 88.5 Antibiotic 01 3.8 Don't know 02 7.7 Incubation period (days) Up to 3 04 1.3 Up to 7 19 6.3 Up to 14 272 90.2	Headache	165	54.8	
Anosmia 133 44.2 Diarrhea 110 36.5 Drug available for COVID-19 Yes 26 8.6 No 260 86.4 Both drug and vaccine 06 2 Which drug is available? (n=26) Hydroxychloroquine 23 88.5 Antibiotic 01 3.8 Don't know 02 7.7 Incubation period (days) Up to 3 04 1.3 Up to 7 19 6.3 Up to 14 272 90.2	Runny nose	157	52.2	
Drug available for COVID-19 Yes 26 8.6 No 260 86.4 Both drug and vaccine 06 2 Which drug is available? (n=26) Hydroxychloroquine 23 88.5 Antibiotic 01 3.8 Don't know 02 7.7 Incubation period (days) Up to 3 04 1.3 Up to 7 19 6.3 Up to 14 272 90.2		133	44.2	
Yes 26 8.6 No 260 86.4 Both drug and vaccine 06 2 Which drug is available? (n=26) Hydroxychloroquine 23 88.5 Antibiotic 01 3.8 Don't know 02 7.7 Incubation period (days) Up to 3 04 1.3 Up to 7 19 6.3 Up to 14 272 90.2	Diarrhea	110	36.5	
Yes 26 8.6 No 260 86.4 Both drug and vaccine 06 2 Which drug is available? (n=26) Hydroxychloroquine 23 88.5 Antibiotic 01 3.8 Don't know 02 7.7 Incubation period (days) Up to 3 04 1.3 Up to 7 19 6.3 Up to 14 272 90.2				
Both drug and vaccine 06 2 Which drug is available? (n=26) Hydroxychloroquine 23 88.5 Antibiotic 01 3.8 Don't know 02 7.7 Incubation period (days) Up to 3 04 1.3 Up to 7 19 6.3 Up to 14 272 90.2			8.6	
vaccine Which drug is available? (n=26) Hydroxychloroquine 23 88.5 Antibiotic 01 3.8 Don't know 02 7.7 Incubation period (days) Up to 3 04 1.3 Up to 7 19 6.3 Up to 14 272 90.2	No	260	86.4	
Which drug is available? (n=26) Hydroxychloroquine 23 88.5 Antibiotic 01 3.8 Don't know 02 7.7 Incubation period (days) Up to 3 04 1.3 Up to 7 19 6.3 Up to 14 272 90.2		06	2	
Hydroxychloroquine 23 88.5 Antibiotic 01 3.8 Don't know 02 7.7 Incubation period (days) Up to 3 04 1.3 Up to 7 19 6.3 Up to 14 272 90.2				
Antibiotic 01 3.8 Don't know 02 7.7 Incubation period (days) Up to 3 04 1.3 Up to 7 19 6.3 Up to 14 272 90.2	·		88.5	
Don't know 02 7.7 Incubation period (days) Up to 3 04 1.3 Up to 7 19 6.3 Up to 14 272 90.2				
Incubation period (days) Up to 3 04 1.3 Up to 7 19 6.3 Up to 14 272 90.2	Don't know	02	7.7	
Up to 3 04 1.3 Up to 7 19 6.3 Up to 14 272 90.2	Incubation period (days)			
Up to 7 19 6.3 Up to 14 272 90.2		04	1.3	
Up to 14 272 90.2		19	6.3	
-	•	272	90.2	
		06	2	

Most of the study participants were practicing preventive measures effectively. Majority of the friends and family members were washing their hands, often. Majority of the respondents i.e., 297 (98.7%) practiced social distancing followed by 282 (93.7%) participants avoided crowded areas as they believed that the disease spread could be stopped if they practiced these measures.

Out of 301 participants included in the online survey majority i.e., 284 (94.4%) informed that the source of information regarding COVID-19 is by consulting with the health workers, followed by newspaper, television, conversation with colleagues and with family and friends, radio stations and social media respectively.

Table 3: Practices carried out by respondents against COVID-19 and source of information regarding COVID-19 (n=301).

Variables	Numbers	Percentage (%)		
Family and friends washing their hands				
Not often	07	2.3		
Often	186	61.8		
Very often	108	35.9		
Social distancing/avoid c	Social distancing/avoid crowded areas			
My family and friends avoid crowded areas	297	98.7		
My family and friends follow social distancing	282	93.7		
Source of information regarding COVID-19				
Consultation with health workers	284	94.4		
Daily/weekly newspaper	231	76.7		
Public TV channels	210	69.8		
Conversation with colleagues	184	61.1		
Conversation with family and friends	172	57.1		
Radio stations	163	54.2		
Social media	81	26.9		

On asking about the reason for why they are worried about COVID-19 majority i.e., 223 (74%) responded that the disease is highly contagious, 219 (72.7%) told that no vaccine is available, 183 (60.8%) said that the disease is dangerous and life threatening. This shows that community are really worried and uncertain about the threat of this new disease.

Table 4: Perceived threat of respondents regarding COVID-19 (n=301).

Variables	Number	Percentage (%)		
Worried about novel corona				
Highly contagious	223	74		
No vaccine available	219	72.7		
Dangerous and life threatening	183	60.8		
I doubt if I get infected, I won't recover fully	150	49.8		
Family members might get infected	139	46.2		
I may contract infection from anybody	02	0.6		




Figure 1: Cues to action in relation to COVID-19.

Majority of the respondents have brought changes in their lifestyle which is evident from the above answers. Participants were practicing social distancing fully. Measures like avoiding touching eyes, nose and mouth, covering mouth when coughing, and washing with soap and water, wear facemask and avoid gathering respectively, avoiding close contact with someone who is infected, was practiced very effectively. Other measures were Staying home when sick, self-quarantine, ensuring a balanced diet, using disinfectant doing regular exercise, drinking warm water taking food supplements, avoided meat, and use of antibiotics (Figure 1).

The Table 5 describes the perceived benefits towards complying to the restrictions regarding the pandemic of COVID-19. Majority of respondents agreed to get the vaccine if available and if people who have visited outbreak should be quarantined, community facilities such as schools or kindergartens should be closed and major events should be cancelled and international trips should be avoided. One should leave the house only for urgent reasons and not unnecessarily.

Table 5: Perceived benefits of COVID-19.

	NT 1	D (
Variables	Numbers,	Percentage		
	(n=301)	(%)		
If vaccine is availab				
Yes	273	90.7		
No	28	9.3		
People who have vis	sited outbreak sh	ould		
quarantined				
Yes	298	99		
No	01	0.3		
Don't know	02	0.7		
Avoid certain people on basis of international travel				
history				
Yes	202	67.1		
No	80	26.6		
Don't know	19	6.3		
Community facilitie	es such as schools	or		
kindergartens shou	ld be closed			
Yes	298	99		
No	00	00		
Don't know	03	1		
In risk areas, major	In risk areas, major events should be cancelled by			
the organizers		·		
Yes	298	99		
No	02	0.7		
Don't know	01	0.3		
Should only be allowed to leave his house for health				
professionals or urgent reasons				
Yes	292	97		
No	05	1.7		
Don't know	04	1.3		




Figure 2: Perception of affect- COVID-19 to me feels (1-7 Likert scale).

Above Figure 2 shows the perceptions of affect assessed as affect towards COVID-19. The affects illustrated were mainly stress, feeling helpless, fear about novel corona virus, rate of spread, media hyped the situation about the news of COVID-19. It was observed that 36.5% participants felt that that disease was spreading fast and

majority participants i.e., 38.5% did not have any fear regarding the disease. 13% participants felt that there was quite media hype while 16.6% also felt that there was no media hype and the disease is indeed dangerous. 18.3% felt helpless while 28.6% did not feel stressed.




Figure 3: Community preparedness measures.

Above Figure 3 illustrates the preparedness measures adopted by the study participants towards impending pandemic. About 33.9% of the participants bought extra medicines, 36.5% bought extra food, 46.8% bought extra medicines that they usually take, 31.9% bought disinfection on a large scale, 86% participants stayed away from social events, 88% of them cancelled flights or train rides, 91.7% of them cancelled holiday trips, 88% of the study participants-imposed restrictions on children going out of the house.




Figure 4: Perceptions of susceptibility to an infection with COVID-19.




Figure 5: Perceptions of severity of contracting COVID-19.

Perceived susceptibility was found to be moderate and accounts for 33.9% and 26.2% of the study participants perceived that the severity of contracting novel corona virus is very less accounting for 26.2% (Figure 5).

DISCUSSION

In the present study 301 majority of the participants i.e., 162 (53.8%) of them were male. Majority were in the age group of 21-30 years with the mean and standard deviation of 30±11.3. According to Nazli et al, the mean age of the respondents 38.38±12.34.6 Majority i.e., 125 (41.5%) were Doctor by occupation. Only 24 (8%) had chronic illness. 98.7% of the study participants were aware about COVID-19 which is similar to the finding of a research conducted by Jose et al, in which 99.3% of the participants were aware. In the present study majority i.e., 293 (97.4%) knew that COVID-19 is transmitted via respiratory droplets, followed by 219 (72.8%) touching contaminated surface/object. According to Roy et al, it was observed that only 29.5% of the participants responded that the virus spreads through multiple modes like touching, kissing, sneezing, and food study.8 In the present study, 299 (99.3%) informed that people aged more than 60 years are at risk of getting COVID-19 infection followed by individual who have chronic lung diseases. In the present study majority i.e., 288 (95.7%) of the study participants responded fever as a symptom of COVID-19 followed by shortness of breath, cough which is similar to the findings of the study conducted by Cvetkovic et al in which majority of the respondents (98.2%) noted that common symptoms include fever, dry cough.9 Roy et al, conducted a study and observed that only 18.2% regarded fever as a symptom of COVID-19, which is a major symptom.8 98.7% practiced social distancing followed as they believed that the disease spread could be stopped if they practice this measure. 88.7% of the study participants-imposed restrictions on children going out of the house. Among 301 participants

included in the study majority i.e., 284 (94.4%) informed that the source of information regarding COVID-19 is by consulting with the health workers, followed by newspaper, television. In the present study majority i.e., 223 (74%) responded that the disease is highly contagious, 219 (72.7%) told that no vaccine is available.

Limitations

The study is limited to the people who had smartphone's, and who were well versed with English. Study has been done amongst educated population hence it cannot be generalized to the whole population.

CONCLUSION

The study participants had adequate awareness and knowledge regarding the novel corona virus. Perceptions have a great role in behavioral change therefore

All efforts should be focused on improving the perceived susceptibility, severity, benefits, the cues for action, especially in a new pandemic scenario which requires a quick behavioral change.

Funding: No funding sources Conflict of interest: None declared

Ethical approval: The study was approved by the

Institutional Ethics Committee

REFERENCES

- 1. Lee Baggley D, DeLongis A, Voorhoeave P, Greenglass E. Coping with the threat of severe acute respiratory syndrome: Role of threat appraisals and coping responses in health behaviors. Asian J Social Psychol. 2004;7(1):9-23.
- Wang Y, Wang Y, Chen Y, Qin Q. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19)

- implicate special control measures. J med virol. 2020;92(6):568-76.
- 3. Shanmugaraj B, Siriwattananon K, Wangkanont K, Phoolcharoen W. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian Pac J Allergy Immunol. 2020;38(1):10-8.
- 4. Jiang F, Deng L, Zhang L, Cai Y, Cheung CW, Xia Z. Review of the clinical characteristics of coronavirus disease 2019 (COVID-19). Journal of general internal medicine. 2020;4:1-5.
- 5. World Health Organization. Coronavirus disease (COVID-19): weekly epidemiological, update 1.
- 6. Nazli T, Raheem A, Kishore J. Perceptions and Practices of the Adult Population in Response to SARS-CoV-2 Pandemic in India. Epidemiol Int. 2020;5(2):10-6.
- Jose R, Narendran M, Bindu A, Beevi N, Manju L, Benny PV. Public perception and preparedness for the pandemic COVID 19: A Health Belief Model approach. Clin Epidemiol Global Health. 2020.
- Roy D, Tripathy S, Kar SK, Sharma N, Verma SK, Kaushal V. Study of knowledge, attitude, anxiety & perceived mental healthcare need in Indian population during COVID-19 pandemic. Asian J Psychiatry. 2020:102083.
- 9. Cvetković VM, Nikolić N, Radovanović Nenadić U, Öcal A, Noji KE, Zečević M. Preparedness and Preventive Behaviors for a Pandemic Disaster Caused by COVID-19 in Serbia. Int J Environmental Res Public Health. 2020;17(11):4124.

Cite this article as: Jain A, Toppo M, Gour D, Verma S. Perception, practices and preparedness of the adult population in response to SARS CoV-2 pandemic in India. Int J Community Med Public Health 2021;8:2266-71.